Abstract:Background: Non-alcoholic fatty liver disease (NAFLD), recognized as a chronic liver condition, has emerged as one of the most prevalent worldwide. This study explores the impact of artesunate (ART) on lipid accumulation and inflammatory factors within NAFLD model cells. Methods: LO2 cells were subjected to treatment with oleic acid (OA) to establish NAFLD cell model. Subsequently, these cells were categorized into distinct groups: a control group, an OA group, an OA + 2.5 μm ART group, and an OA + 5 μm ART group. The activity of LO2 cells was determined using the Cell Counting Kit-8 (CCK-8) method. The presence of intracellular lipid droplets was examined through oil red O staining. Levels of triglycerides (TG), total cholesterol (TC), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were evaluated using enzyme-linked immunosorbent assay (ELISA). Additionally, the protein expressions of nucleotide-binding oligomerization domain (NOD), leucine-rich repeat (LRR), and pyrin domain-containing protein 3 (NLRP3), Cleaved caspase-1, N-terminus of Gasdermin-D (GSDMD-N), and apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) were measured via Western blot assay. Results: In comparison to the control group, the OA group exhibited a significant increase in the contents of lipid droplets, TC, and TG (p < 0.01). Notably, ART effectively reversed the impact of OA (p < 0.01). Following OA stimulation, there was a pronounced elevation in the levels of IL-6 (p < 0.01), IL-1β (p < 0.01), and TNF-α (p < 0.05). In comparison to the OA group, the 2.5 μm ART group showed no significant difference in TNF-α content (p > 0.05), while the 5 μm ART group significantly reduced TNF-α content (p < 0.05). Furthermore, both the 2.5 μm ART (p < 0.05) and 5 μm ART (p < 0.01) groups notably reduced IL-1β and IL-6 content. When compared to the control group, the expressions of NLRP3, ASC, GSDMD-N, and Cleaved caspase-1 in the OA group significantly increased (p < 0.01). ART, however, mitigated this heightened expression trend (p < 0.05). Conclusions: ART demonstrated a reduction in TC and TG content, improvement in the deposit of intracellular lipid droplets, and a decrease in the release of inflammatory factors in LO2 cells. This effect was achieved through the regulation of the NLRP3 inflammasome, presenting a novel approach to the treatment of NAFLD.

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice

Artemether Ameliorates Non‐Alcoholic Steatohepatitis by Restraining Cross‐Talk Between Lipotoxicity‐Induced Hepatic Hepatocytes and Macrophages

Ganoderic Acid A Ameliorates Non-Alcoholic Streatohepatitis (NASH) Induced by High-Fat High-Cholesterol Diet in Mice

Artesunate Inhibits Lipid Accumulation and Inflammation by Regulating the NLRP3 Inflammasome in Nonalcoholic Fatty Liver Disease

Artesunate alleviates hepatic fibrosis induced by multiple pathogenic factors and inflammation through the inhibition of LPS/TLR4/NF-κB signaling pathway in rats

Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress

Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling

Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses

Allyl Isothiocyanate Ameliorates Lipid Accumulation and Inflammation in Nonalcoholic Fatty Liver Disease Via the Sirt1/AMPK and NF-κB Signaling Pathways.

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice

Arctiin attenuates lipid accumulation, inflammation and oxidative stress in nonalcoholic fatty liver disease through inhibiting MAPK pathway

Artesunate Induces Ferroptosis in Hepatic Stellate Cells and Alleviates Liver Fibrosis via the ROCK1/ATF3 Axis

Artemether ameliorates acetaminophen-induced liver injury through Nrf2 pathway

Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet

Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity

Artesunate Alleviates Schistosomiasis-Induced Liver Fibrosis by Downregulation of Mitochondrial Complex Ⅰ Subunit NDUFB8 and Complex Ⅲ Subunit UQCRC2 in Hepatic Stellate Cells.

Hepalatide Ameliorated Progression of Nonalcoholic Steatohepatitis in Mice.

Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy

A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway

Atractylodin alleviates nonalcoholic fatty liver disease by regulating Nrf2-mediated ferroptosis

Anti-malarial artesunate ameliorates atherosclerosis by modulating arterial inflammatory responses via inhibiting the NF-κB–NLRP3 inflammasome pathway